{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:36:00Z","timestamp":1768566960988,"version":"3.49.0"},"posted":{"date-parts":[[2024,6,7]]},"group-title":"Obstetrics and Gynecology","reference-count":25,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,6,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To determine the safety, tolerance, and adherence to self-administered intravaginal 5% fluorouracil (5FU) cream as adjuvant therapy following cervical intraepithelial neoplasia grade 2 or 3 (CIN2\/3) treatment among women living with HIV (WLWH) in Kenya.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>\n                    A Phase I Pilot trial was performed among 12 WLWH in Kenya, aged 18\u201349 years between March 2023-February 2024 (\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/Clinicaltrial.gov\">Clinicaltrials.gov<\/jats:ext-link>\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05362955\">NCT05362955<\/jats:ext-link>\n                    ). Participants self-administered 2g of 5FU intravaginally every other week for eight applications. Safety was assessed using a standardized grading scale, and adherence was evaluated using self-report, inspection of used applicators, and weighing of the study drug.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>\n                    The mean age and CD4 count were 43.9 years and 781 cells\/mm\n                    <jats:sup>3<\/jats:sup>\n                    , respectively. Seven (58%) had an 8\n                    <jats:sup>th<\/jats:sup>\n                    -grade education or less. All 12 reported at least one grade I adverse event (AE), 1 (8%) reported a grade 2 AE, no grade 3 or 4 AEs were reported. Increased vaginal discharge (n=9, 75%) and irritation (n=5, 42%), with a mean duration of 3.2 and 2.8 days, respectively, were the most commonly reported AEs. Provider-observed AEs included grade 1 cervical erythema and superficial abrasions. All participants tolerated all eight 5FU doses, and 96% adherence was demonstrated.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Self-administered 5FU following CIN2\/3 treatment among WLWH in Kisumu, Kenya, was safe, tolerable, and associated with high adherence. Randomized trials are needed to investigate whether adjuvant 5FU can improve treatment outcomes or serve as primary cervical precancer treatment in sub-Saharan Africa. A self-administered therapy may be transformative in increasing access to treatment and, hence, secondary prevention of cervical cancer.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2024.06.06.24308548","type":"posted-content","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T16:10:20Z","timestamp":1717776620000},"source":"Crossref","is-referenced-by-count":1,"title":["Safety and adherence to self-administered intravaginal 5-fluorouracil cream following cervical intraepithelial neoplasia (CIN) 2\/3 treatment among HIV-positive women in Kenya: A phase 1 clinical trial"],"prefix":"10.64898","author":[{"given":"Chemtai","family":"Mungo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jackton","family":"Omoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cirilus","family":"Ogollah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antony","family":"Owaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercy","family":"Rop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gershon","family":"Rota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A","family":"Bukusi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Rahangdale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2024061122151071000_2024.06.06.24308548v1.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"2024061122151071000_2024.06.06.24308548v1.2","doi-asserted-by":"publisher","DOI":"10.1177\/0956462413491735"},{"key":"2024061122151071000_2024.06.06.24308548v1.3","unstructured":"WHO. A Global Strategy for elimination of cervical cancer. Accessed March 25, 2020. https:\/\/www.who.int\/activities\/a-global-strategy-for-elimination-of-cervical-cancer"},{"key":"2024061122151071000_2024.06.06.24308548v1.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2017.03.022"},{"key":"2024061122151071000_2024.06.06.24308548v1.5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.14969"},{"key":"2024061122151071000_2024.06.06.24308548v1.6","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34221"},{"key":"2024061122151071000_2024.06.06.24308548v1.7","doi-asserted-by":"publisher","DOI":"10.1002\/IJC.34737"},{"key":"2024061122151071000_2024.06.06.24308548v1.8","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2009.291"},{"key":"2024061122151071000_2024.06.06.24308548v1.9","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.jncimonographs.a003473"},{"key":"2024061122151071000_2024.06.06.24308548v1.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2008.02.012"},{"key":"2024061122151071000_2024.06.06.24308548v1.11","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000002311"},{"key":"2024061122151071000_2024.06.06.24308548v1.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(99)00407-X"},{"key":"2024061122151071000_2024.06.06.24308548v1.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2013.12.042"},{"key":"2024061122151071000_2024.06.06.24308548v1.14","unstructured":"WHO Model Lists of Essential Medicines. World Health Organization."},{"key":"2024061122151071000_2024.06.06.24308548v1.15","doi-asserted-by":"publisher","DOI":"10.1101\/2023.12.13.23299916"},{"key":"2024061122151071000_2024.06.06.24308548v1.16","unstructured":"NIAID NIH. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. Accessed July 27, 2020. https:\/\/rsc.niaid.nih.gov\/sites\/default\/files\/addendum-1-female-genital-grading-table-v1-nov-2007.pdf"},{"key":"2024061122151071000_2024.06.06.24308548v1.17","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0b013e31824790bb"},{"key":"2024061122151071000_2024.06.06.24308548v1.18","unstructured":"Ministry of Health, Nairobi K . Kenya National Cancer Screening Guidelines. Published online 2018:1\u2013122."},{"key":"2024061122151071000_2024.06.06.24308548v1.19","doi-asserted-by":"publisher","DOI":"10.1214\/ss\/1009213286"},{"key":"2024061122151071000_2024.06.06.24308548v1.20","doi-asserted-by":"publisher","DOI":"10.1186\/S12889-022-12547-9"},{"key":"2024061122151071000_2024.06.06.24308548v1.21","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-016-3110-1"},{"key":"2024061122151071000_2024.06.06.24308548v1.22","doi-asserted-by":"publisher","DOI":"10.3332\/ECANCER.2022.1442"},{"key":"2024061122151071000_2024.06.06.24308548v1.23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.14969"},{"issue":"2","key":"2024061122151071000_2024.06.06.24308548v1.24","first-page":"205","article-title":"Chronic ulcerations following topical therapy with 5-fluorouracil for vaginal human papillomavirus-associated lesions","volume":"78","year":"1991","journal-title":"Obstetrics and gynecology"},{"key":"2024061122151071000_2024.06.06.24308548v1.25","doi-asserted-by":"publisher","DOI":"10.1002\/IJGO.14983"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.06.06.24308548","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:02:40Z","timestamp":1768507360000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2024.06.06.24308548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,7]]},"references-count":25,"URL":"https:\/\/doi.org\/10.1101\/2024.06.06.24308548","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1002\/ijgo.16093","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2024,6,7]]},"subtype":"preprint"}}